Breast Cancer

Lenvatinib (Lenvima) plus pembrolizumab (Keytruda) showed early antitumor activity and tolerability in previously treated triple-negative breast cancer patients with advanced solid tumors.

Trial shows that olaparib, a poly ADP ribose polymerase inhibitor that is the first cancer drug to target an inherited genetic fault, can be used successfully to treat prostate cancers with a weakness in the ability to repair damaged DNA.

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer.

Study shows the recurrence rate was within the expected range for breast cancer survivors receiving spironolactone and those who did not.
 

A new test may help direct treatments for patients with rare breast cancer mutations. 

Understanding the role of abemaciclib (Verzenio) in managing patients with hormone receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer is crucial.

It may take cells in different stages of development to cause breast cancer to progress and spread, according to recent research published in eLife.

Figuring out how to target vulnerable cells in breast cancer tumors can help treat the disease more effectively. 
 

Jacob Kettle, PharmD, BCOP, and Allison Butts, PharmD, BCOP, share some future therapies for the management of breast cancer.

The current study found no link between personal use of permanent hair dye and the risk of most cancers or cancer-related mortality.

Jacob Kettle, PharmD, BCOP, and Allison Butts, PharmD, BCOP, consider the influence of COVID-19 on the therapeutic choice for patients.

Oral chemotherapy may be an important option for patients during the COVID-19 pandemic, as it would allow them to receive treatment at home.